Huang Shao-Bin, Zheng Chao-Xu
a Department of Pancreato-biliary Surgery , the First Affiliated Hospital of Sun Yat-Sen University , Guangzhou , China.
Expert Rev Anticancer Ther. 2017 Jan;17(1):89-96. doi: 10.1080/14737140.2017.1266261. Epub 2016 Dec 14.
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the advances in research of gene alterations and epigenetic changes in ICC; it also aims to promote the findings of new biomarkers that can be used to diagnose ICC and to provide novel ideas for the combination of molecular targeted therapies. Expert commentary: Surgical resection is regarded as the most effective curative treatment, although in many cases, resectability and curability are unsatisfactory. Furthermore, many patients are diagnosed at advanced stages and have to resort to chemotherapy, which is rarely curative. Many of the molecular mechanisms of ICC are yet to be determined; once these determinations are made, then ICC may be able to be treated by precise targeted drugs.
肝内胆管癌(ICC)是一种高度恶性的肿瘤。在过去几十年里,全球范围内ICC的发病率一直在上升。涵盖领域:ICC的发病机制是一个复杂的过程,涉及特定基因的改变和表观遗传变化。本综述总结了ICC基因改变和表观遗传变化的研究进展;其目的还在于推动可用于诊断ICC的新生物标志物的发现,并为分子靶向治疗的联合应用提供新思路。专家评论:手术切除被认为是最有效的治愈性治疗方法,尽管在许多情况下,可切除性和治愈率并不理想。此外,许多患者在晚期才被诊断出来,不得不依靠化疗,但化疗很少能治愈。ICC的许多分子机制尚未确定;一旦确定了这些机制,那么ICC或许就能用精确的靶向药物进行治疗。